Human infections due to nontuberculous mycobacteria: The infectious diseases and clinical microbiology specialists' point of view

Future Microbiology

Volumn 10, Issue 9, 2015, Pages 1467-1483

  Guglielmetti, Lorenzo ^a,b,c   Mougari, Faiza ^a,b,d   Lopes, Amanda ^a   Raskine, Laurent ^a,b   Cambau, Emmanuelle ^a,b,d  

^a HÔPITAL LARIBOISIÈRE   (France)

^b Centre National de Reference des Mycobacteries et de la Resistance Aux Antituberculeux   (France)

^c Universidad de Verona   (Italy)

^d UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

AIDS; clarithromycin; cystic fibrosis; iatrogenic infections; lung infection; M. avium; mycobacteria; nontuberculous mycobacteria; NTM; tuberculosis

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; BACTERIUM ISOLATION; DISEASE SEVERITY; HUMAN; IATROGENIC DISEASE; INFECTION PREVENTION; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM KANSASII; MYCOBACTERIUM MARINUM; MYCOBACTERIUM ULCERANS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; SPECIES IDENTIFICATION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; BACTERIAL SKIN DISEASE; CLASSIFICATION; COMPLICATION; CYSTIC FIBROSIS; DRUG EFFECTS; GENETICS; IMMUNOCOMPROMISED PATIENT; MICROBIOLOGY; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; PATHOGENICITY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; HUMANS; IATROGENIC DISEASE; IMMUNOCOMPROMISED HOST; MYCOBACTERIUM AVIUM; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; MYCOBACTERIUM KANSASII; NONTUBERCULOUS MYCOBACTERIA; SKIN DISEASES, BACTERIAL;

EID: 84942762578     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.15.64     Document Type: Review

References (131)

1. Runyon EH, Selin MJ, Harris HW. Distinguishing mycobacteria by the niacin test; a modified procedure. Am. Rev. Tuberc. 79(5), 663-665 (1959).
2. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am. Rev. Respir. Dis. 119(1), 107-159 (1979).
3. Romanus V, Hallander HO, Wahlen P, Olinder-Nielsen AM, Magnusson PH, Juhlin I. Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination coverage. Tuber. Lung Dis. 76(4), 300-310 (1995).
4. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175(4), 367-416 (2007).
5. Mirsaeidi M, Machado RF, Garcia JG, Schraufnagel DE. Nontuberculous mycobacterial disease mortality in the United States, 1999-2010: a population-based comparative study. PLoS ONE 9(3), e91879 (2014).
6. Open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. veterans affairs HIV research consortium
7. Meyers H, Brown-Elliott BA, Moore D et al. An outbreak of Mycobacterium chelonae infection following liposuction. Clin. Infect. Dis. 34(11), 1500-1507 (2002).
8. LPSN bacterio. net. http://www. bacterio. net/mycobacterium. html
9. Mougari F, Guglielmetti L, Lopes A, Raskine L, Cambau E. Mycobactérioses non tuberculeuses hors mycobactérioses cutanées. Revue Encyclopédie Médico Chirurgicale 8-038-C-10 doi:10. 1016/S1166-8598(14)38398-2 (2015) (Epub ahead of print).
10. Springer B, Stockman L, Teschner K, Roberts GD, Bottger EC. Two-laboratory collaborative study on identification of mycobacteria: molecular versus phenotypic methods. J. Clin. Microbiol. 34(2), 296-303 (1996).
11. McNabb A, Eisler D, Adie K et al. Assessment of partial sequencing of the 65-kilodalton heat shock protein gene (hsp65) for routine identification of Mycobacterium species isolated from clinical sources. J. Clin. Microbiol. 42(7), 3000-3011 (2004).
12. Adekambi T, Colson P, Drancourt M. rpoB-based identification of nonpigmented and late-pigmenting rapidly growing mycobacteria. J. Clin. Microbiol. 41(12), 5699-5708 (2003).
13. Roth A, Fischer M, Hamid ME, Michalke S, Ludwig W, Mauch H. Differentiation of phylogenetically related slowly growing mycobacteria based on 16S-23S rRNA gene internal transcribed spacer sequences. J. Clin. Microbiol. 36(1), 139-147 (1998).
14. Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin. Microbiol. Rev. 16(2), 319-354 (2003).
15. Aksamit TR, Philley JV, Griffith DE. Nontuberculous mycobacterial (NTM) lung disease: the top ten essentials. Respir. Med. 108(3), 417-425 (2014).
16. Dhillon SS, Watanakunakorn C. Lady Windermere syndrome: middle lobe bronchiectasis and Mycobacterium avium complex infection due to voluntary cough suppression. Clin. Infect. Dis. 30(3), 572-575 (2000).
17. Mangione EJ, Huitt G, Lenaway D et al. Nontuberculous mycobacterial disease following hot tub exposure. Emerg. Infect. Dis. 7(6), 1039-1042 (2001).
18. Bracker A, Storey E, Yang C, Hodgson MJ. An outbreak of hypersensitivity pneumonitis at a metalworking plant: a longitudinal assessment of intervention effectiveness. Applied Occupation Environ. Hyg. 18(2), 96-108 (2003).
19. Inderlied CB, Kemper CA, Bermudez LE. The Mycobacterium avium complex. Clin. Microbiol. Rev. 6(3), 266-310 (1993).
20. Arend SM, Cerda de Palou E, de Haas P et al. Pneumonia caused by Mycobacterium kansasii in a series of patients without recognised immune defect. Clin. Microbiol. Infect. 10(8), 738-748 (2004).
21. Henriques B, Hoffner SE, Petrini B, Juhlin I, Wahlen P, Kallenius G. Infection with Mycobacterium malmoense in Sweden: report of 221 cases. Clin. Infect. Dis. 18(4), 596-600 (1994).
22. Jenkins PA, Campbell IA. Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five year follow-up of patients receiving standardised treatment. Respir. Med. 97(4), 439-444 (2003).
23. Griffith DE. Emergence of nontuberculous mycobacteria as pathogens in cystic fibrosis. Am. J. Respir. Crit. Care Med. 167(6), 810-812 (2003).
24. Le Bourgeois M, Sermet-Gaudelus I, Catherinot E, Gaillard JL. [Nontuberculous mycobacteria in cystic fibrosis]. Arch. Pediatr. 12(Suppl. 2), S117-S121 (2005).
25. Piersimoni C, Scarparo C. Pulmonary infections associated with non-tuberculous mycobacteria in immunocompetent patients. Lancet Infect. Dis. 8(5), 323-334 (2008).
26. Shitrit D, Priess R, Peled N, Bishara G, Shlomi D, Kramer MR. Differentiation of Mycobacterium kansasii infection from Mycobacterium tuberculosis infection: comparison of clinical features, radiological appearance, and outcome. Eur. J. Clin. Microbiol. Infect. Dis. 26(10), 679-684 (2007).
27. Cattamanchi A, Nahid P, Marras TK et al. Detailed analysis of the radiographic presentation of Mycobacterium kansasii lung disease in patients with HIV infection. Chest 133(4), 875-880 (2008).
28. Andrejak C, Lescure FX, Pukenyte E et al. Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax 64(4), 291-296 (2009).
29. Lai KK, Stottmeier KD, Sherman IH, McCabe WR. Mycobacterial cervical lymphadenopathy. Relation of etiologic agents to age. JAMA 251(10), 1286-1288 (1984).
30. Wolinsky E. Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up. Clin. Infect. Dis. 20(4), 954-963 (1995).
31. Ikeue T, Furuta K, Nakaji H, Morita K, Sugita T, Nishiyama H. [Cervical lymphadenitis caused by Mycobacterium avium in an immunocompetent adult]. Kekkaku 87(10), 659-662 (2012).
32. Tortoli E. Clinical manifestations of nontuberculous mycobacteria infections. Clin. Microbiol. Infect. 15(10), 906-910 (2009).
33. Rindi L, Garzelli C. Genetic diversity and phylogeny of Mycobacterium avium. Infect. Genet. Evol. 21, 375-383 (2014).
34. El Helou G, Viola GM, Hachem R, Han XY, Raad II. Rapidly growing mycobacterial bloodstream infections. Lancet Infect. Dis. 13(2), 166-174 (2013).
35. Hawkins C, Qi C, Warren J, Stosor V. Catheter-related bloodstream infections caused by rapidly growing nontuberculous mycobacteria: a case series including rare species. Diagn. Microbiol. Infect. Dis. 61(2), 187-191 (2008).
36. Sizaire V, Nackers F, Comte E, Portaels F. Mycobacterium ulcerans infection: control, diagnosis, and treatment. Lancet Infect. Dis. 6(5), 288-296 (2006).
37. Cambau E, Aubry A. Mycobacterium marinum. In: Tuberculosis and mycobacterial infections (6th Edition). Schlossberg D (Ed.). ASM Press, 586-600 (2010).
38. Portaels F, Meyers WM, Ablordey A et al. First cultivation and characterization of Mycobacterium ulcerans from the environment. PLoS Negl. Trop. Dis. 2(3), e178 (2008).
39. Aubry A, Chosidow O, Caumes E, Robert J, Cambau E. Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Arch. Intern. Med. 162(15), 1746-1752 (2002).
40. Edelstein H. Mycobacterium marinum skin infections. Report of 31 cases and review of the literature. Arch. Intern. Med. 154(12), 1359-1364 (1994).
41. Carbonne A, Brossier F, Arnaud I et al. Outbreak of nontuberculous mycobacterial subcutaneous infections related to multiple mesotherapy injections. J. Clin. Microbiol. 47(6), 1961-1964 (2009).
42. Conaglen PD, Laurenson IF, Sergeant A, Thorn SN, Rayner A, Stevenson J. Systematic review of tattoo-associated skin infection with rapidly growing mycobacteria and public health investigation of a cluster in Scotland, 2010. Euro. Surveill. 18(32), 20553 (2013).
43. Regnier S, Cambau E, Meningaud JP et al. Clinical management of rapidly growing mycobacterial cutaneous infections in patients after mesotherapy. Clin. Infect. Dis. 49(9), 1358-1364 (2009).
44. Piersimoni C, Scarparo C. Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent persons. Emerg. Infect. Dis. 15(9), 1351-1358 (2009).
45. Yeh JJ, Wang YC, Sung FC, Kao CH. Rheumatoid arthritis increases the risk of nontuberculosis mycobacterial disease and active pulmonary tuberculosis. PLoS ONE 9(10), e110922 (2014).
46. Winthrop KL, Iseman M. Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy. Nat. Rev. Rheumatol. 9(9), 524-531 (2013).
47. Hirsch R, Miller SM, Kazi S, Cate TR, Reveille JD. Human immunodeficiency virus-associated atypical mycobacterial skeletal infections. Semin. Arthritis Rheum. 25(5), 347-356 (1996).
48. Petitjean G, Fluckiger U, Scharen S, Laifer G. Vertebral osteomyelitis caused by non-tuberculous mycobacteria. Clin. Microbiol. Infect. 10(11), 951-953 (2004).
49. Danesh-Clough T, Theis JC, van der Linden A. Mycobacterium xenopi infection of the spine: a case report and literature review. Spine (Phila. PA 1976) 25(5), 626-628 (2000).
50. Feller M, Huwiler K, Stephan R et al. Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. Lancet Infect. Dis. 7(9), 607-613 (2007).
51. Ferroni A, Vu-Thien H, Lanotte P et al. Value of the chlorhexidine decontamination method for recovery of nontuberculous mycobacteria from sputum samples of patients with cystic fibrosis. J. Clin. Microbiol. 44(6), 2237-2239 (2006).
52. Doggett JS, Strasfeld L. Disseminated Mycobacterium genavense with pulmonary nodules in a kidney transplant recipient: case report and review of the literature. Transpl. Infect. Dis. 13(1), 38-43 (2011).
53. Lindeboom JA, Bruijnesteijn van Coppenraet LE, van Soolingen D, Prins JM, Kuijper EJ. Clinical manifestations, diagnosis, and treatment of Mycobacterium haemophilum infections. Clin. Microbiol. Rev. 24(4), 701-717 (2011).
54. Dai J, Chen Y, Lauzardo M. Web-accessible database of hsp65 sequences from Mycobacterium reference strains. J. Clin. Microbiol. 49(6), 2296-2303 (2011).
55. Tortoli E. Microbiological features and clinical relevance of new species of the genus Mycobacterium. Clin. Microbiol. Rev. 27(4), 727-752 (2014).
56. European Centre for Disease Prevention and Control. Mastering the basics of TB control: development of a handbook on TB diagnostic methods. Stockholm, Sweden, ECDC (2011).
57. van Ingen J, Boeree MJ, van Soolingen D, Mouton JW. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist. Update 15(3), 149-161 (2012).
58. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob. Agents Chemother. 53(4), 1367-1376 (2009).
59. Nash KA, Zhang Y, Brown-Elliott BA, Wallace RJ Jr. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J. Antimicrob. Chemother. 55(2), 170-177 (2005).
60. Bastian S, Veziris N, Roux AL et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob. Agents Chemother. 55(2), 775-781 (2011).
61. Koh WJ, Jeon K, Lee NY et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am. J. Respir. Crit. Care Med. 183(3), 405-410 (2011).
62. Kim SY, Kim CK, Bae IK et al. The drug susceptibility profile and inducible resistance to macrolides of Mycobacterium abscessus and Mycobacterium massiliense in Korea. Diagn. Microbiol. Infect. Dis. 81(2), 107-111 (2015).
63. Cho YJ, Yi H, Chun J et al. The genome sequence of 'Mycobacterium massiliense' strain CIP 108297 suggests the independent taxonomic status of the Mycobacterium abscessus complex at the subspecies level. PLoS ONE 8(11), e81560 (2013).
64. Meier A, Heifets L, Wallace RJ Jr. et al. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J. Infect. Dis. 174(2), 354-360 (1996).
65. Wallace RJ, Jr., Meier A, Brown BA et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob. Agents Chemother. 40(7), 1676-1681 (1996).
66. Prammananan T, Sander P, Brown BA et al. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J. Infect. Dis. 177(6), 1573-1581 (1998).
67. Nessar R, Reyrat JM, Murray A, Gicquel B. Genetic analysis of new 16S rRNA mutations conferring aminoglycoside resistance in Mycobacterium abscessus. J. Antimicrob. Chemother. 66(8), 1719-1724 (2011).
68. Brown-Elliott BA, Iakhiaeva E, Griffith DE et al. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J. Clin. Microbiol. 51(10), 3389-3394 (2013).
69. Klein JL, Brown TJ, French GL. Rifampin resistance in Mycobacterium kansasii is associated with rpoB mutations. Antimicrob. Agents Chemother. 45(11), 3056-3058 (2001).
70. Yoshida S, Suzuki K, Tsuyuguchi K et al. [Detection of rpoB mutations in rifampicin-resistant Mycobacterium kansasii]. Kekkaku 81(7), 475-479 (2006).
71. de Moura VC, da Silva MG, Gomes KM et al. Phenotypic and molecular characterization of quinolone resistance in Mycobacterium abscessus subsp. bolletii recovered from postsurgical infections. J. Med. Microbiol. 61(Pt 1), 115-125 (2012).
72. Revel V, Cambau E, Jarlier V, Sougakoff W. Characterization of mutations in Mycobacterium smegmatis involved in resistance to fluoroquinolones. Antimicrob. Agents Chemother. 38(9), 1991-1996 (1994).
73. Susceptibility testing of Mycobacteria, Nocardia, and Other Aerobic Actinomycetes; Approved Stabdard-Second Edition. Clinical and Laboratory Standards Institute (CLSI) document M24-A2 (ISBN1-56238-746-4) (2011).
74. Maurer FP, Castelberg C, Quiblier C, Bottger EC, Somoskovi A. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus. J. Antimicrob. Chemother. 69(6), 1559-1563 (2014).
75. Kanatani MS, Guglielmo BJ. The new macrolides. Azithromycin and clarithromycin. West. J. Med. 160(1), 31-37 (1994).
76. Dautzenberg B, Piperno D, Diot P, Truffot-Pernot C, Chauvin JP. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France. Chest 107(4), 1035-1040 (1995).
77. Dautzenberg B, Truffot C, Legris S et al. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. Am. Rev. Respir. Dis. 144(3 Pt 1), 564-569 (1991).
78. Tanaka E, Kimoto T, Tsuyuguchi K et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am. J. Respir. Crit. Care Med. 160(3), 866-872 (1999).
79. Benson CA, Williams PL, Currier JS et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin. Infect. Dis. 37(9), 1234-1243 (2003).
80. Murray MP, Laurenson IF, Hill AT. Outcomes of a standardized triple-drug regimen for the treatment of nontuberculous mycobacterial pulmonary infection. Clin. Infect. Dis. 47(2), 222-224 (2008).
81. Wallace RJ Jr, Brown-Elliott BA, McNulty S et al. Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest 146(2), 276-282 (2014).
82. van Ingen J, Egelund EF, Levin A et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am. J. Respir. Crit. Care Med. 186(6), 559-565 (2012).
83. Hasegawa N, Nishimura T, Ohtani S et al. Therapeutic effects of various initial combinations of chemotherapy including clarithromycin against Mycobacterium avium complex pulmonary disease. Chest 136(6), 1569-1575 (2009).
84. Kim EY, Chi SY, Oh IJ et al. Treatment outcome of combination therapy including clarithromycin for Mycobacterium avium complex pulmonary disease. Korean J. Intern. Med. 26(1), 54-59 (2011).
85. Griffith DE, Brown BA, Murphy DT, Girard WM, Couch L, Wallace RJ, Jr. Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients. J. Infect. Dis. 178(1), 121-126 (1998).
86. Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir. Med. 101(1), 130-138 (2007).
87. Peloquin CA, Berning SE, Nitta AT et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin. Infect. Dis. 38(11), 1538-1544 (2004).
88. Jeong BH, Jeon K, Park HY et al. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 191(1), 96-103 (2015).
89. Koh WJ, Hong G, Kim SY et al. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. Antimicrob. Agents Chemother. 57(5), 2281-2285 (2013).
90. Olivier KN, Shaw PA, Glaser TS et al. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann. Am. Thorac. Soc. 11(1), 30-35 (2014).
91. Griffith DE, Brown-Elliott BA, Langsjoen B et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 174(8), 928-934 (2006).
92. Nelson KG, Griffith DE, Brown BA, Wallace RJ, Jr. Results of operation in Mycobacterium avium-intracellulare lung disease. Ann. Thorac. Surg. 66(2), 325-330 (1998).
93. Shiraishi Y, Nakajima Y, Takasuna K, Hanaoka T, Katsuragi N, Konno H. Surgery for Mycobacterium avium complex lung disease in the clarithromycin era. Eur. J. Cardiothorac. Surg. 21(2), 314-318 (2002).
94. Mitchell JD, Bishop A, Cafaro A, Weyant MJ, Pomerantz M. Anatomic lung resection for nontuberculous mycobacterial disease. Ann. Thorac. Surg. 85(6), 1887-1892; discussion 1892-1883 (2008).
95. Lindeboom JA, Kuijper EJ, Bruijnesteijn van Coppenraet ES, Lindeboom R, Prins JM. Surgical excision versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children: a multicenter, randomized, controlled trial. Clin. Infect. Dis. 44(8), 1057-1064 (2007).
96. Lindeboom JA. Surgical treatment for nontuberculous mycobacterial (NTM) cervicofacial lymphadenitis in children. J. Oral. Maxillofac. Surg. 70(2), 345-348 (2012).
97. Zeharia A, Eidlitz-Markus T, Haimi-Cohen Y, Samra Z, Kaufman L, Amir J. Management of nontuberculous mycobacteria-induced cervical lymphadenitis with observation alone. Pediatr. Infect. Dis. J. 27(10), 920-922 (2008).
98. Shafran SD, Singer J, Zarowny DP et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N. Engl. J. Med. 335(6), 377-383 (1996).
99. May T, Brel F, Beuscart C et al. Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida. Clin. Infect. Dis. 25(3), 621-629 (1997).
100. Gordin FM, Sullam PM, Shafran SD et al. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin. Infect. Dis. 28(5), 1080-1085 (1999).
101. Sun Z, Zhang Y. Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide. Antimicrob. Agents Chemother. 43(3), 537-542 (1999).
102. Pezzia W, Raleigh JW, Bailey MC, Toth EA, Silverblatt J. Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev. Infect. Dis. 3(5), 1035-1039 (1981).
103. Griffith DE, Brown-Elliott BA, Wallace RJ, Jr. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin. Infect. Dis. 37(9), 1178-1182 (2003).
104. Santin M, Dorca J, Alcaide F et al. Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease. Eur. Respir. J. 33(1), 148-152 (2009).
105. Wallace RJ Jr, Dunbar D, Brown BA et al. Rifampin-resistant Mycobacterium kansasii. Clin. Infect. Dis. 18(5), 736-743 (1994).
106. Brown-Elliott BA, Nash KA, Wallace RJ Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin. Microbiol. Rev. 25(3), 545-582 (2012).
107. Lang-Lazdunski L, Offredo C, Le Pimpec-Barthes F, Danel C, Dujon A, Riquet M. Pulmonary resection for Mycobacterium xenopi pulmonary infection. Ann. Thorac. Surg. 72(6), 1877-1882 (2001).
108. Sarfo FS, Phillips R, Asiedu K et al. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob. Agents Chemother. 54(9), 3678-3685 (2010).
109. Nienhuis WA, Stienstra Y, Thompson WA et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 375(9715), 664-672 (2010).
110. WHO. Treatment of Mycobacterium ulcerans disease (Buruli ulcer): guidance for health workers. World Health Organ. (2012). www. who. int
111. Aubry A, Jarlier V, Escolano S, Truffot-Pernot C, Cambau E. Antibiotic susceptibility pattern of Mycobacterium marinum. Antimicrob. Agents Chemother. 44(11), 3133-3136 (2000).
112. Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. Mycobacterium abscessus: a new antibiotic nightmare. J. Antimicrob. Chemother. 67(4), 810-818 (2012).
113. Jeon K, Kwon OJ, Lee NY et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am. J. Respir. Crit. Care Med. 180(9), 896-902 (2009).
114. Lyu J, Jang HJ, Song JW et al. Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs. Respir. Med. 105(5), 781-787 (2011).
115. Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst. Rev. 12, CD010004 (2014).
116. Wallace RJ Jr, Tanner D, Brennan PJ, Brown BA. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann. Intern. Med. 119(6), 482-486 (1993).
117. Falkinham JO 3rd. Epidemiology of infection by nontuberculous mycobacteria. Clin. Microbiol. Rev. 9(2), 177-215 (1996).
118. Le Dantec C, Duguet JP, Montiel A, Dumoutier N, Dubrou S, Vincent V. Occurrence of mycobacteria in water treatment lines and in water distribution systems. Appl. Environ. Microbiol. 68(11), 5318-5325 (2002).
119. Delafont V, Mougari F, Cambau E et al. First evidence of amoebae-mycobacteria association in drinking water network. Environ. Sci. Technol. 48(20), 11872-11882 (2014).
120. Whiley H, Keegan A, Giglio S, Bentham R. Mycobacterium avium complex-the role of potable water in disease transmission. J. Appl. Microbiol. 113(2), 223-232 (2012).
121. Bukh AS, Roslev P. Mycobacterium avium complex in day care hot water systems, and persistence of live cells and DNA in hot water pipes. Curr. Microbiol. 68(4), 428-439 (2014).
122. Shafran SD. Prevention and treatment of disseminated Mycobacterium avium complex infection in human immunodeficiency virus-infected individuals. Int J. Infect. Dis. 3(1), 39-47 (1998).
123. Astagneau P, Desplaces N, Vincent V et al. Mycobacterium xenopi spinal infections after discovertebral surgery: investigation and screening of a large outbreak. Lancet 358(9283), 747-751 (2001).
124. Couderc C, Carbonne A, Thiolet JM et al. [Non-tuberculous mycobacterial infections related to esthetic care in France, 2001-2010]. Med. Mal. Infect. 41(7), 379-383 (2011).
125. Greendyke R, Byrd TF. Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. Antimicrob. Agents Chemother. 52(6), 2019-2026 (2008).
126. Ricketts WM, O'Shaughnessy TC, van Ingen J. Human-to-human transmission of Mycobacterium kansasii or victims of a shared source Eur. Respir. J. 44(4), 1085-1087 (2014).
127. Bryant JM, Grogono DM, Greaves D et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 381(9877), 1551-1560 (2013).
128. Mougari F, Raskine L, Ferroni A et al. Clonal relationship and differentiation among Mycobacterium abscessus isolates as determined using the semiautomated repetitive extragenic palindromic sequence PCR-based DiversiLab system. J. Clin. Microbiol. 52(6), 1969-1977 (2014).
129. Fangous MS, Mougari F, Gouriou S et al. Classification algorithm for subspecies identification within the Mycobacterium abscessus species, based on matrix-assisted laser desorption ionization-time of flight mass spectrometry. J. Clin. Microbiol. 52(9), 3362-3369 (2014).
130. Quinlan P, Phelan E, Doyle M. Matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry (MS) for the identification of mycobacteria from MBBacT ALERT 3D liquid cultures and Lowenstein-Jensen (LJ) solid cultures. J. Clin. Pathol. 229-235 (2014).
131. Menzies D, Nahid P. Update in tuberculosis and nontuberculous mycobacterial disease 2012. Am. J. Respir. Crit. Care Med. 188(8), 923-927 (2013).